Category: Active Surveillance
Why Choose the Sperling Prostate Center for Active Surveillance?
With Active Surveillance on the rise, one would think that doctors who support AS for their prostate cancer patients have similar commitment and protocols. A new study (Sep. 2016) in the British Journal of Urology International (BJUI) spells out 8 areas of qualitative differences among AS doctors: physician comfort with active surveillance protocol selection beliefs keep readingUncertainty and Anxiety during Active Surveillance
The word is out: Patients with early stage, low risk prostate cancer have often been rushed into radical prostatectomy when many of them could have afforded to wait to seek treatment—possibly for years. Untold numbers of men were left with urinary and sexual problems that lasted for months, or were never fully resolved. For low keep readingActive Surveillance and Testosterone Replacement Therapy
The fact that an opinion has been widely held is no evidence whatever that it is not utterly absurd. – Bertrand Russell What man over the age of, say, 45 doesn’t look back—perhaps nostalgically—on the lusty days of yore? Somewhere between the ages of eighteen to thirty, men reach a sexual peak in which desire keep readingActive Surveillance: Things You Might Not Have Thought About
The number of prostate cancer patients who opt for active surveillance (AS) is rising. The most important reason men go on AS is to avoid the risks that accompany whole-gland treatments. In fact, it’s so important to patients that according to a Dutch study, 30% who were not considered candidates for AS chose it anyway keep reading
Multiparametric MRI Adds Value to Surveillance Monitoring
It’s always reassuring to receive affirmation, especially when offering a leading edge medical program to prostate cancer patients. Such was the case for us at the Sperling Prostate Center with the December, 2015 publication of a UCLA Medical Center study on the value-added of multiparametric MRI during Active Surveillance (AS). The authoritative Journal of Urology keep readingThe Right Way to do Active Surveillance
We know that the use of Active Surveillance (AS) as a way to hold off on prostate cancer (PCa) treatment is on the rise. Concerns about overtreatment, such as doing a prostatectomy on a patient who only has a small Gleason 3+3 tumor, stem from two recognized realities: Insignificant PCa may be slow-growing (indolent) and keep readingToo Fat for Active Surveillance?
I have written on the importance of a healthy lifestyle, especially diet and nutrition, which is correlated with preventing prostate cancer (PCa) and other diseases. (NOTE: You can read some of my related blogs from links at the end of this one.) I came across a new multi-center Italian study that addresses the question: does keep readingStatins and Prostate Cancer: An Update
Last December I posted a blog entry on the possibility that statins, a class of cholesterol-lowering drugs, can reduce the risk of developing aggressive prostate cancer (PCa). If you’re interested, I summarized the relationship between how statins control cholesterol and scientific theories about the connection with PCa; you can read it at https://sperlingprostatecenter.com/statins-prostate-cancer/. I try keep readingActive Surveillance, Depression and Anxiety
There’s been a noticeable uptick in urologists recommending active surveillance (AS) for patients diagnosed with early stage, low risk prostate cancer. However, according to a new British study, nearly a quarter of men on AS will become depressed and anxious... keep reading